Parthenon Therapeutics Showcases New Precision Oncology Technology Designed to Breakdown Barriers in Immune-excluded Tumors
November 16, 2022
– Patient-derived biomarker and preclinical data demonstrate significant opportunity to address immune-excluded tumors, such as colorectal, NSCLC, ovarian, pancreas, and TNBC
– First in human clinical trial of lead asset, PRTH-101, expected to initiate 3Q23
Boston, MA -- November 16, 2022 – Parthenon Therapeutics, a precision oncology company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME), today unveiled its precision medicine approach to address cancers with hight unmet need, at the Stifel Healthcare Conference.
“We are delighted to showcase our pipeline and technology to the scientific community and anticipate that we will pioneer a new approach to treating patients with immune-excluded tumors. Specifically, immune exclusivity describes a distinct category of TME where a patient’s T-cells are unable to attack a tumor due to the formation of a barrier around the tumor cells. Our data have shown over 50% of solid tumors are immune-excluded, indicating a significant unmet need for these patients,” said Laurent Audoly, co-founder and Chief Executive Officer of Parthenon Therapeutics. “We also presented our lead asset, PRTH-101, which targets DDR1 (Discoidin Domain Receptor 1) to open up the mechanical barrier that characterizes immune-excluded tumors, and thus make the tumors vulnerable to treatment. We are excited to be developing one of the first therapeutics and patient selection strategy to address this class of tumors, and we anticipate providing more details in the upcoming months. Notably, the second half of 2023 will be a catalyst as we will initiate our first-in-human clinical study in a well-defined patient population.”